Clinical Trial Update: Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253 [Phase 3]

View source ↗

Summary

This update analyzes HBV-specific immune responses in HBeAg-negative chronic hepatitis B patients treated with Pegasys (peginterferon alfa-2a) in the Phase 3 ML…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 3 | Status: COMPLETED